Panelists discuss how maintenance therapy should be tailored based on risk profiles, with standard-risk patients receiving single-agent lenalidomide while high-risk patients may benefit from ...
Maintenance therapy is given after initial treatment for multiple myeloma. It aims to control your cancer and prevent progression. The type of maintenance therapy you receive depends on whether your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback